BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. Business Review
Business Overview
TrustScore Analysis
Our preliminary analysis has revealed key insights about BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.'s performance and market presence. Here‘s a summary of our findings:
Positive highlights
- No positive highlights identified
Negative highlights
- Is relatively new
- No employer brand presence on career platforms
- May not have contact information online
- No official business profile found on major search engines
Corporate Information
21012
Manufacture of pharmaceutical products and preparations for human use (e.g. tableted products)
Wholesale of medicinal and pharmaceutical products (Western)
Contact Information for BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.
BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.'s Business Reviews
No reviews available
Review This Business
Recently transacted with BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.?
How would you rate your overall satisfaction?
Be a part of the community and help others make informed decisions by sharing your experience. Your feedback not only helps the business improve but also assists other customers in choosing the best services and products available.
Public Preview of BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.
This is only a preview of the TrustScore results for BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD., showcasing a few facets of its business that we have analysed.
Established Stage
A established brand is one that has achieved a strong, recognisable presence in its market or industry. These brands are well-known, trusted and often considered as key brands in their space. They have a significant loyal customer base, a clear and consistent identity, and a proven track record of success and growth.
Key Characteristics
- Strong Brand Recognition: BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. is likely widely recognised by its target audience and beyond. These brands are usually household names with history, regional or global reach and financial might.
- Market Leadership: BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. is often seen as a leader or key player in its industry. They dominate the market and often set trends for others to follow.
- Loyal Customer Base: It has a large and dedicated following of customers after 4 years of operation, often associated with brand value and loyalty.
- Consistent Identity: The brand’s mission, values, and visual identity are well-defined and consistently applied. The narrative is often relational and recognisable.
- Diverse Offerings: It has a robust and varied portfolio of products or services that cater to a wide range of customer needs. After sales service and customer support are usually well aligned with company’s offerings.
- Scaled Operations: The brand has the infrastructure, team, and processes to support its size and reach.
- Financial Stability: It generates steady revenue and often has significant market share.
Why It Matters
- BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. represent stability, trust, and excellence.
- They have proven their ability to adapt, innovate, and thrive over time. However, even established brands must continue to evolve to stay relevant in a changing market.
The company's address is not in use by other companies, providing a unique and credible business location. BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. is relatively new, having been operational for less than a year. Companies that have been established for a longer period of time are generally considered more reliable and trustworthy.
BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. has no presence on career platforms and provides no public information about its work environment or employee satisfaction. This lack of transparency may indicate less focus on employee well-being or difficulty in attracting talent, potentially impacting BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.'s long-term success.
The company is not blacklisted by CaseTrust, which is a positive indicator of its credibility. The company is not on the MAS Enforcement List, which is a positive indicator of its compliance with financial regulations.
BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD. may not have accessible contact information online, which dilutes engagement and credibility. The company has no official business profile on major search engines. This absence makes it difficult for potential customers to verify the company's legitimacy or get in touch, potentially raising suspicions about its credibility.
Content Locked
Sign in to view the analysis and detailed metrics for BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.
Sign In to ContinueAssociated News for BIONTECH PHARMACEUTICALS ASIA PACIFIC PTE. LTD.
Children are not more prone to getting infected with Covid-19: Experts
She added that this will be a concern if they transmit the virus to vulnerable people in their household who could develop a severe form of the disease. Prof Tambyah said: "Hence, the idea of vaccinating this age group is a way to protect the vulnerable." The Health Sciences Authority on Tuesday extended its authorisation for those aged 12 to 15 to receive the Pfizer-BioNTech vaccine. The Health Ministry and Education Ministry will announce when vaccinations will be extended to this age group in due course.
22 May 2021
Pfizer-BioNTech COVID-19 vaccine safe for those aged 12 to 15, says committee in response to open letter by doctors
The use of the Pfizer-BioNTech vaccine in children aged 12 to 15 has been assessed to be safe and effective, Singapore's expert committee on COVID-19 vaccination said on Friday (May 21) in response to an open letter by 12 doctors. The doctors had called for children to be given other types of COVID-19 vaccines - and not the mRNA ones - saying the "long-term side effects are unknown and unstudied" for mRNA vaccines. The two COVID-19 vaccines approved for use in Singapore - Pfizer-BioNTech and Moderna - are both based on mRNA technology.
21 May 2021
Singapore approves Pfizer-BioNTech vaccine for teens; Rotterdam to ‘open up’ for Eurovision
Meanwhile, Singapore authorised the use of the Pfizer-BioNTech Covid vaccine to teenagers aged 12 to 15, officials said on Tuesday, in a first for Asia. The city-state’s Health Sciences Authority extended the use of the vaccine -- currently only approved for individuals aged 16 and above -- after reviewing clinical data submitted by the manufacturer. Singaporean authorities "assessed that the Pfizer-BioNTech covid-19 vaccine demonstrated high safety and efficacy for this age group of 12 to 15 years old, which is consistent with what we have observed for the adult population," Health Minister Ong Ye Kung said at a press conference.
Global companies are also still investing in Singapore. For example, BioNTech announced this month it will pump in "hundreds of millions of dollars" to set up its South-east Asia headquarters and open a vaccine manufacturing facility in Singapore, as part of plans to establish a footprint in Asia. The move will see the German biotech company create over 80 jobs in the Republic in areas such as production, management and quality control.
Global companies are also still investing in Singapore. For example, BioNTech announced this month it will pump in "hundreds of millions of dollars" to set up its South-east Asia headquarters and open a vaccine manufacturing facility in Singapore, as part of plans to establish a footprint in Asia. The move will see the German biotech company create over 80 jobs in the Republic in areas such as production, management and quality control.
BioNTech to put up manufacturing site in Singapore - Asean Economist
Biopharmaceutical New Technologies or BioNTech has chosen Singapore to expand its manufacturing roots in Southeast Asia. The Nasdaq-listed immunotherapy firm on May 10 said it will set up in the city-state its regional headquarters and a fully integrated mRNA manufacturing facility that will produce vaccines against Covid-19 and other therapeutics for infectious diseases and cancer. “Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said BioNTech chief Dr. Ugur Sahin.
16 May 2021
FAQs
Frequently Asked Questions
Have questions? We’re here to help you.
Scam.SG's TrustScore is an AI-driven engine that evaluates a business's trustworthiness by analysing data such as customer feedback, behavioral patterns, and compliance records. This comprehensive assessment results in a numerical score reflecting the entity's reliability.
Similar Companies
ORIENTAL PEARL PTE. LTD.
ORGANON ASIA PACIFIC SERVICES PTE. LTD.
HAISCO PHARMACEUTICALS PTE. LTD.
AKESO BIOPHARMA PTE. LTD.
SAMANVAY HEALTHCARE PTE. LTD.